# Beijing Pearl Biotechnology Limited Liability Company

Source: https://onco.cc/companies/beijing-pearl-biotechnology-limited-liability-company/  
OnCo record `beijing-pearl-biotechnology-limited-liability-company` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Beijing Pearl Biotechnology Limited Liability Company is a Chinese developer in Beijing that sponsors 3 registered cancer trials of PLB1001 and Temozolomide.

## Summary

Beijing Pearl Biotechnology Limited Liability Company appears on ClinicalTrials.gov as the industry sponsor of 3 interventional cancer trials (phase 2/3, 3), testing PLB1001, Temozolomide in glioblastoma, non-small cell lung cancer, non-small cell lung cancer. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Tags: ctgov-sponsor; china; registry-only
- HQ: Beijing, China
- Type: biotech

## Sources

- ClinicalTrials.gov: trials sponsored by Beijing Pearl Biotechnology Limited Liability Company: https://clinicaltrials.gov/search?spons=Beijing%20Pearl%20Biotechnology%20Limited%20Liability%20Company

## Connected records

- trials: [A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)](https://onco.cc/trials/nct05989542/), [A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).](https://onco.cc/trials/nct06105619/), [A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive](https://onco.cc/trials/nct06930794/)

---
JSON: https://onco.cc/api/v1/entities/beijing-pearl-biotechnology-limited-liability-company.json